

Table S1 UVA and MVA for LRRFS and DMFS

| Variables | Number | LRRFS | | | | | | DMFS | | | | | |
|------------------------------------|--------|----------------|-------------|-------|------|--------------|---------|----------------|-------------|-------|------|--------------|---------|
| | | At 5 years (%) | UVA P value | HR | AR | MVA 95% CI | P value | At 5 years (%) | UVA P value | HR | AR | MVA 95% CI | P value |
| Gender | | | 0.159 | | | | | | 0.06 | | | | |
| Male | 35 | 74.8 | | | | | | 71.8 | | | | | |
| Female | 25 | 91.5 | | | | | | 87.1 | | | | | |
| Age (years) | | | 0.222 | | | | | | 0.485 | | | | |
| ≤52 | 31 | 88.4 | | | | | | 75.7 | | | | | |
| >52 | 29 | 74.8 | | | | | | 80.5 | | | | | |
| Perineural invasion | | | 0.601 | | | | | | 0.676 | | | | |
| No | 41 | 80.9 | | | | | | 81 | | | | | |
| Yes | 19 | 88.9 | | | | | | 76.7 | | | | | |
| Major never involvement | | | 0.215 | | | | | | 0.024 | 2.115 | 21.1 | 0.521–8.583 | 0.008 |
| Negative | 32 | 89.5 | | | | | | 89.3 | | | | | |
| Positive | 28 | 74.5 | | | | | | 68.2 | | | | | |
| Extra-parenchymal extension | | | 0.84 | | | | | | 0.476 | | | | |
| No | 26 | 82.4 | | | | | | 83.8 | | | | | |
| Yes | 34 | 84.2 | | | | | | 77.3 | | | | | |
| Primary site | | | 0.591 | | | | | | 0.762 | | | | |
| Parotid gland | 34 | 82.5 | | | | | | 79.4 | | | | | |
| Submandibular gland | 17 | 75.3 | | | | | | 68.8 | | | | | |
| Sublingual gland | 9 | 88.9 | | | | | | 74.1 | | | | | |
| T stage | | | 0.337 | | | | | | 0.13 | | | | |
| T1–T2 | 14 | 85.7 | | | | | | 92.3 | | | | | |
| T3–T4b | 46 | 80.9 | | | | | | 74.7 | | | | | |
| N stage | | | 0.173 | | | | | | 0.014 | | | | |
| N0 | 41 | 83.7 | | | | | | 86.1 | | | | | |
| N1 | 8 | – | | | | | | – | | | | | |
| N2b | 8 | – | | | | | | 60 | | | | | |
| N2c | 3 | – | | | | | | – | | | | | |
| Clinical stage | | | 0.495 | | | | | | 0.049 | | | | |
| I–II | 11 | 85.7 | | | | | | 100 | | | | | |
| III–IVb | 49 | 82 | | | | | | 73.8 | | | | | |
| Margin | | | 0.029 | 5.064 | 28.8 | 1.211–21.187 | 0.026 | | 0.055 | 6.367 | 24.8 | 1.524–26.603 | 0.011 |
| Positive | 53 | 85.9 | | | | | | 81.9 | | | | | |
| Negative | 7 | 57.1 | | | | | | 57.1 | | | | | |
| Skin involvement | | | 0.136 | | | | | | 0.932 | | | | |
| No | 55 | 85.8 | | | | | | 78.3 | | | | | |
| Yes | 5 | 40 | | | | | | 80 | | | | | |
| Interval from surgery to RT (days) | | | 0.239 | | | | | | 0.157 | 6.231 | 12.5 | 1.503–25.829 | 0.012 |
| ≤30 | 30 | 88.9 | | | | | | 84.4 | | | | | |
| >30 | 30 | 75 | | | | | | 71.9 | | | | | |

P was calculated using log-rank test. UVA, univariable analysis; MVA, multivariable analysis; LRRFS, locoregional relapse-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; AR, absolute risk; CI, confidence interval.